What Is Market-Share Liability in Tort Law?

Market-share liability is a tort rule that lets you recover damages from the makers of a harmful product even when you cannot prove which specific manufacturer made the unit that injured you. Instead of pointing to one defendant, you sue a group of companies that produced the identical product, and each one pays a percentage of your damages equal to its share of the market at the time you were exposed.¹ Courts created the doctrine for a narrow situation: a generic product, many manufacturers, and an injury that surfaces so long after exposure that identifying the source is impossible.

Why the Normal Rule Blocks These Cases

In a standard personal injury or product liability case, you have to prove causation. That means showing that but for a particular defendant’s conduct, your injury would not have happened.² If a defective appliance burns you, the brand name is on the product and the receipt is in a drawer. The rule works.

It stops working when hundreds of companies make the same unbranded chemical, when pharmacies have long since discarded their records, and when the injury does not appear for twenty years. In that situation, every injured person loses at the causation step, no matter how strong the rest of the case is. Market-share liability exists to prevent that outcome.

The Fact Pattern the Doctrine Was Built For

The doctrine traces to diethylstilbestrol, or DES, a synthetic estrogen prescribed to pregnant women starting in the late 1940s to prevent miscarriage and morning sickness. DES was never patented, so roughly 300 companies manufactured it using an identical formula. The FDA pulled it from pregnancy-related use in 1971, but by then about three million women had taken it.³

Their daughters later developed cancers and reproductive abnormalities. The pills were chemically indistinguishable, the records were gone, and no plaintiff could prove whose version her mother swallowed. The California Supreme Court addressed the resulting dead end in Sindell v. Abbott Laboratories in 1980 and created market-share liability as the way out.

What You Have to Prove

The doctrine does not remove your burden of proof. It swaps the identification requirement for a different set of conditions. To proceed on a market-share theory, you need to show:

The product was fungible, meaning every manufacturer’s version was chemically or physically interchangeable with no distinguishing features between brands.¹
You cannot identify the specific manufacturer, and that inability is not your fault. If you destroyed records or failed to investigate, the doctrine will not help you.¹
The product caused your injury. You still have to prove the category of product harmed you, just not whose version.
The defendants you sue represent a substantial share of the market. One or two companies is not enough.¹

Fungibility is the hardest condition to meet. Any meaningful difference between brands, whether in formulation, design, or construction, tends to defeat it. Courts have rejected the doctrine for products like cotton flannelette fabric where manufacturers used distinct weaves and patterns.

The Burden Shift

Once you establish the elements above, something unusual happens. Each defendant manufacturer must then prove it did not make the product that injured you. In Conley v. Boyle Drug Co., the Florida Supreme Court held that DES manufacturers were liable for a plaintiff’s cancer unless each defendant could affirmatively prove it did not make the drug at the time of the plaintiff’s injury.¹ A defendant that cannot carry that burden stays in the case and pays its share.

A manufacturer can escape by showing it could not have produced the specific product. The most effective proof is non-participation in the relevant market: the company did not make the drug during the years the plaintiff was exposed, or did not sell it in the geographic area where the purchase occurred. Formulation defenses work only when the difference is meaningful. For DES, courts rejected arguments based on minor variations in inactive ingredients or pill coatings because the active compound was identical. When a defendant successfully exculpates itself, its share is redistributed among the remaining defendants.

How Damages Get Divided

Awards are proportional. A manufacturer that held 15% of the market pays 15% of the damages; one with 30% pays 30%.¹ This differs sharply from joint and several liability, where any one defendant can be forced to pay the whole judgment and absorb the shares of insolvent co-defendants. Under market-share liability, each manufacturer’s exposure is generally capped at its percentage.⁴

Defining the Relevant Market

Percentages only mean something once a court defines the market being measured, and courts have answered that question differently. New York uses a national market because determining a smaller geographic market was deemed impractical. The original Sindell case focused on the California market, where the plaintiff sued ten California DES manufacturers. The geographic scope matters because a company might hold 25% of the national market but only 5% in the state where the plaintiff’s mother bought the drug.

Time matters as well. Courts measure share at the moment of exposure, not at the time of the lawsuit. For DES, that meant reconstructing market data from the 1950s and 1960s, often through economic or statistical experts.

Does Your State Even Allow It?

Market-share liability is not available everywhere. California adopted it in Sindell, and Washington, New York, Wisconsin, and Florida have followed with their own versions. Each of those states handles details like market definition and exculpation differently.

Several state supreme courts have refused to adopt it. Missouri rejected the doctrine in Zafft v. Eli Lilly & Co. and held plaintiffs to the traditional identification requirement. Iowa rejected it in Mulcahy v. Eli Lilly & Co. on policy grounds. Illinois concluded in Smith v. Eli Lilly & Co. that the doctrine is fundamentally flawed regardless of how it is applied.³ Some federal courts have declined to apply it when predicting how a state would rule. If you are in a state that has rejected the doctrine, no amount of strong evidence will substitute for identifying the specific manufacturer.

Why Cases Beyond DES Usually Fail

Plaintiffs have tried to extend market-share liability to lead paint, firearms, tobacco, and asbestos. Most of these efforts have failed, and the reason is almost always fungibility. Courts find that different manufacturers’ versions of the product have distinguishing characteristics, which keeps them from being interchangeable in the way DES was.

Lead paint came closest. Plaintiffs argued that white lead carbonate pigment was chemically identical across makers. The Wisconsin Supreme Court, in Thomas v. Mallett, allowed a childhood lead poisoning case to proceed under Wisconsin’s version of the doctrine. That remains an outlier. Most courts have found that paint products vary in lead concentration, additives, and formulation enough to defeat fungibility.

The practical reality is that market-share liability is narrow. It fits the pattern that produced it: a genuinely identical product, made by many companies over a long period, causing injuries with a latency so long that identification is impossible through no fault of the plaintiff. The further your case drifts from that pattern, the less likely a court is to apply the doctrine.

1
LII / Legal Information Institute. Market Share Liability
2
Legal Information Institute (LII) / Cornell Law School. Negligence
3
Vanderbilt Law Review. Market Share Liability – A Current Assessment of a Decade-Old Doctrine
4
Legal Information Institute (LII) / Cornell Law School. Joint and Several Liability